Biosimilars: Economic Issues for IP Litigation
In July 2021, the U.S. Food and Drug Administration granted a determination of interchangeability to a biosimilar drug for the first time. This approval has...
CRA’s life sciences litigation support services are grounded in a comprehensive understanding of pharmaceutical, biotechnology, medical device, and diagnostic markets. For more than 30 years, our experts have consulted with major life science companies, law firms, and regulatory agencies around the globe. We provide clients with the industry and analytical expertise needed to solve our clients’ most complex issues.
CRA has a reputation for delivering rigorous analysis and expert testimony. Economic expertise is complemented by experience assisting life sciences companies with business and policy issues. This combination allows CRA to provide effective expert testimony and support.
Engagements
- 01CRA addressed a claim that a company had improperly failed to pay required development milestones upon termination of a drug development programIn litigation before the Delaware Court of Chancery, a CRA expert was asked to address the basis for a company’s decision to terminate the development of a...View engagement
- 02Economic analysis in a product hopping litigationThis case involved a blood thinner drug whose initial patent had expired. The brand company improved the product and obtained additional patents on those...View engagement
- 03Economic analysis of generic test specification standardsThis matter involved scientific tests for generic drug closeness to the brand, as required by the FDA. The plaintiff alleged deceptive conduct within the...View engagement
Meet our team
![Gregory Bell | Expert Witness | Charles River Associates]()
Gregory K. BellGroup Vice President and Life Sciences Practice Leader
Boston
+1-617-425-3357 gbell@crai.com![]()
![Andrew Tepperman | Life Sciences Litigation | Charles River Associates]()